Multidrug, Anti-HIV Amorphous Solid Dispersions: Nature and Mechanisms of Impacts of Drugs on Each Other’s Solution Concentrations
Open Access
- 25 September 2017
- journal article
- research article
- Published by American Chemical Society (ACS) in Molecular Pharmaceutics
- Vol. 14 (11) , 3617-3627
Abstract
Drug therapy has been instrumental in prolonging the lives of patients infected by human immunodeficiency virus (HIV). In order to combat development of resistance, therapies involving three or more drugs in combination are recommended by the World Health Organization (WHO) to suppress HIV and prevent development of acquired immune deficiency syndrome (AIDS). It is desirable for multidrug combinations to be coformulated into single dosage forms where possible, to promote patient convenience and adherence to dosage regimens, for which amorphous solid dispersion (ASD) is particularly well-suited. We investigated multidrug ASDs of three model anti-HIV drugs, ritonavir (Rit), etravirine (Etra), and efavirenz (Efa), in cellulosic polymer matrices. We hypothesized that the presence of multiple drugs would reduce crystallization tendency, thereby providing stable, supersaturating formulations for bioavailability enhancement. We explored new ASD polymers including cellulose acetate suberate (DSSub 0.9, CASub) and cellulose acetate adipate propionate (DSAd 0.9, CAAdP), and control commercial cellulosic polymers including 6-carboxycellulose acetate butyrate (CCAB) and carboxymethyl cellulose acetate butyrate (CMCAB). We succeeded in preparing three-drug ASDs containing very high drug loadings (45% drug total; 15% of each drug); each polymer tested was effective at stabilizing the amorphous drugs in the solid phase, as demonstrated by XRD, SEM, and DSC studies. In pH 6.8 dissolution studies ASDs released each anti-HIV drug over 8 h, affording supersaturated solutions of each drug, but unexpectedly failing in some cases to reach maximum possible supersaturation. In a second set of dissolution studies (pH 6.8), the cause of the observed solution concentration limitations was investigated by studying release from single- and two-drug ASDs. Concentrations of Rit, Etra, and Efa achieved from three-drug ASDs were higher than those achieved from crystalline drugs. Surprisingly, however, there was a decrease in the achieved drug concentrations of both Rit and Efa when they dissolved together, while Etra solution concentration was enhanced by the presence of Rit and Efa in the ASD. We demonstrate that these effects have to do primarily with solution phase interactions between the anti-HIV drugs, rather than from the drugs influencing each other’s release rate, and we suggest that such observations may indicate an important, previously inadequately recognized, and general phenomenon for ASDs containing multiple hydrophobic drugs.Keywords
Funding Information
- Division of Industrial Innovation and Partnerships (IIP-1312157)
- American Association of Pharmaceutical Scientists
- Institute for Critical Technologies and Applied Science, Virginia Tech
- Division of Materials Research (DMR-1308276, DMR-1309218)
- Macromolecules Innovation Institute, Virginia Polytechnic Institute and State University
This publication has 39 references indexed in Scilit:
- Impact of Polymers on Crystal Growth Rate of Structurally Diverse Compounds from Aqueous SolutionMolecular Pharmaceutics, 2013
- Maintaining Supersaturation in Aqueous Drug Solutions: Impact of Different Polymers on Induction TimesCrystal Growth & Design, 2012
- A Win–Win Solution in Oral Delivery of Lipophilic Drugs: Supersaturation via Amorphous Solid Dispersions Increases Apparent Solubility without Sacrifice of Intestinal Membrane PermeabilityMolecular Pharmaceutics, 2012
- Synthesis of Cellulose Adipate DerivativesBiomacromolecules, 2011
- Excipient-Mediated Supersaturation Stabilization in Human Intestinal FluidsMolecular Pharmaceutics, 2011
- Physicochemical Properties of the Amorphous Drug, Cast Films, and Spray Dried Powders to Predict Formulation Probability of Success for Solid Dispersions: EtravirineJournal of Pharmaceutical Sciences, 2011
- Clinical Pharmacokinetics and Pharmacodynamics of EtravirineClinical Pharmacokinetics, 2009
- Drug delivery systems in HIV pharmacotherapy: What has been done and the challenges standing aheadJournal of Controlled Release, 2009
- HIV Drug ResistanceNew England Journal of Medicine, 2004
- Prospects for the FutureScience, 2002